| Literature DB >> 34992468 |
Abebe Muche Belete1, Alemu Adela Tefera1, Mekasha Getnet2, Adisu Asefa1, Yared Asmare Aynalem2, Wondimeneh Shibabaw Shiferaw2.
Abstract
BACKGROUND: Hypovitaminosis D is associated with bone fracture and cardiovascular disease in patients receiving antiretroviral therapy. Currently, there are few data on the magnitude of hypovitaminosis D in people living with HIV in Sub-Saharan country. Therefore, the present study determines the magnitude of hypovitaminosis D in people living with HIV and its associated factors in Ethiopia.Entities:
Keywords: Ethiopia; HIV; antiretroviral therapy; vitamin D
Year: 2021 PMID: 34992468 PMCID: PMC8710583 DOI: 10.2147/HIV.S345827
Source DB: PubMed Journal: HIV AIDS (Auckl) ISSN: 1179-1373
General Characteristics of Study Participants at HIV Clinic of DBSH, Debre Berhan, Ethiopia, 2021
| Variable | Category | Frequency | Percent |
|---|---|---|---|
| Sex | Male | 64 | 37.4 |
| Female | 107 | 62.6 | |
| Age in years | 18–30 | 47 | 27.5 |
| 31–43 | 90 | 52.6 | |
| >44 | 34 | 19.9 | |
| Yrs since diagnosis | <7 | 69 | 40.4 |
| >7 | 102 | 59.6 | |
| Yrs on HAART | <6 | 47 | 27.5 |
| >6 | 124 | 72.5 | |
| Yrs on current regimen | <2 | 141 | 82.5 |
| >2 | 30 | 17.5 | |
| Last CD4 count in cells/mm3 | <200 | 32 | 18.7 |
| 200–500 | 63 | 36.8 | |
| >500 | 76 | 44.4 | |
| Type of ART | TDF/3TC/EFV | 14 | 8.2 |
| TDF/3TC/LPV/r | 8 | 4.7 | |
| TDF/3TC/ATV/r | 39 | 22.8 | |
| TDF/3TC/DTG | 110 | 64.3 | |
| Drug adherence | Good | 133 | 77.8 |
| Fair | 34 | 19.9 | |
| Poor | 4 | 2.3 | |
| Viral load in copies/mL | Undetectable(<50 copies/mL) | 131 | 76.6 |
| <1000 copies/mL | 26 | 15.2 | |
| ≥1000 copies/mL | 14 | 8.2 | |
| Variables | Category | Frequency | Percent |
| BMI | <18 | 31 | 18.1 |
| 18–24.9 | 111 | 64.9 | |
| 25–26.9 | 25 | 14.6 | |
| >30 | 4 | 2.3 | |
| Alcohol drink | No | 165 | 96.5 |
| Yes | 6 | 3.5 | |
| Tobacco smoking status | Current smoker | 3 | 1.8 |
| Previous smoker | 2 | 1.2 | |
| Nonsmoker | 166 | 97.1 | |
| Use of corticosteroid | No | 169 | 98.8 |
| Yes | 2 | 1.2 | |
| Multivitamin take | No | 164 | 95.9 |
| Yes | 7 | 4.1 | |
| Crohn’s ds, ulcerative colitis | No | 169 | 98.8 |
| Yes | 2 | 1.2 | |
| Suns cream use | No | 137 | 80.1 |
| Yes | 34 | 19.9 | |
| Sun exposure in minutes per day | <5 mi | 4 | 2.3 |
| 5–15 min | 3 | 1.8 | |
| 15–30 min | 15 | 8.8 | |
| >30min | 149 | 87.1 | |
| Use of tanning booth | No | 126 | 73.7 |
| Yes | 45 | 26.3 | |
| Other medication | No | 159 | 93.0 |
| Yes | 12 | 7.0 | |
| Comorbidities | No | 159 | 93.0 |
| Yes | 12 | 7.0 | |
| Diarrhea in the past 2 week | No | 146 | 85.4 |
| Yes | 25 | 14.6 | |
| Rheumatoid arthritis | No | 164 | 95.9 |
| Yes | 7 | 4.1 | |
| HBV/HCV coinfection | No | 171 | 100 |
| Yes | 0 | 0 |
Abbreviations: HAART, highly active antiretroviral therapy; ART, antiretroviral therapy; Yrs, years; BMI, body mass index.
Bivariate and Multivariate Logistic Regression Analysis of Vitamin D Deficiency with Independent Variables, Adult HIV Patients at DBSH, Debre Berhan, Ethiopia, 2021
| Variables | Category | Vitamin D Deficiency | COR (95% CI) | AOR (95% CI) | |
|---|---|---|---|---|---|
| Yes | No | ||||
| Sex | Male | 40(62.5) | 24(37.5) | 1 | |
| Female | 89(83.2) | 18(16.8) | 2.967(1.450–6.071)* | 3.01(1.381–6.561)** | |
| Age | 18–30 | 37(80.4) | 9(19.6) | 1 | |
| 31–43 | 64(71.1) | 26(28.9) | 0.599(0.254–1.414) | ||
| >44 | 27(79.4) | 7(20.6) | 0.938(0.311–2.834) | ||
| Physical exercise | No | 69(68.3) | 32(31.7) | 1 | |
| Yes | 60(85.7) | 10(14.3) | 2.783(1.263–6.130) | 2.609(0.980–6.949) | |
| Alcohol drinking | No | 124(75.2) | 41(24.8) | 1 | |
| Yes | 5(83.3) | 1(16.7) | 1.653(0.188–14.565) | ||
| Smoking status | Currently | 2(66.7) | 1(33.3) | 1 | |
| Quitted | 2(100.0) | 0(0.0) | – | ||
| Never | 125(75.3) | 41(24.7) | 1.524(0.135–17.250) | ||
| Use of sunscreen | No | 98(71.5) | 39(28.5) | 1 | |
| Yes | 31(91.2) | 3(8.8) | 4.112(1.188–14.236)* | 1.633(0.269–9.905) | |
| Sun exposure | <5 mi | 2(50.0) | 2(50.0) | 1 | |
| 5–15 min | 3(100.0) | 0(0.0) | – | ||
| 15–30 min | 11(73.3) | 4(26.7) | 2.75(0.284–26.607) | ||
| >30min | 113(75.8) | 36(24.2) | 3.139(0.427–23.090) | ||
| Used a tanning booth | No | 90(71.4) | 36(28.6) | 1 | |
| Yes | 39(86.7) | 6(13.3) | 2.6(1.013–6.672)* | 0.831(0.221–3.122) | |
| CD4 | <200 | 11(34.4) | 21(65.6) | 1 | |
| 200–500 | 18(28.6) | 45(71.4) | 1.31(0.526–3.256) | ||
| >500 | 13(17.1) | 63(82.9) | 2.538(0.989–6.516) | ||
| Yrs since diagnosis | <7 | 58(74.4) | 20(25.6) | 1 | |
| >7 | 71(76.3) | 22(23.7) | 1.113(0.554–2.236) | ||
| Yrs on HAART | <6 | 65(74.7) | 22(25.3) | 1 | |
| >6 | 64(76.2) | 20(23.8) | 1.083(0.539–2.175) | ||
| Current regimen duration | <2 | 104(77.0) | 31(23.0) | 1 | |
| >2 | 25(69.4) | 11(30.6) | 0.677(0.300–1.530) | ||
| Regimen | EFV | 9(64.3) | 5(35.7) | 1 | |
| LPV/r | 7(87.5) | 1(12.5) | 0.257(0.024–2.732) | ||
| ATV/r | 27(69.2) | 12(30.8) | 0.8(0.221–2.899) | ||
| DTG | 86(78.2) | 24(21.8) | 0.502(0.154–1.64) | ||
Notes: *Statistically significant by univariate logistic regression; **Statistically significant by multivariate logistic regression.
Abbreviations: COR, crude odds ratio; AOR, adjusted odds ratio; CI, confidence interval; EFV, efaverinze; LPV/r, ritonavir-boosted lopinavir; ATV/r, ritonavir-boosted atazanavir; DTG, dolultegravir.